Phuturdex › Diseases › Uterine Hemorrhage
Drugs in development · updated 30 October 2026
Uterine Hemorrhage: drugs in development
As of 30 October 2026 there are 2 active clinical trials (recruiting or ongoing, phases I–III) on 3 drugs for uterine Hemorrhage. 0 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Ferric derisomaltoseMonoferric® | III | 1 | NCT05304442 |
| Ferrous Sulfate | III | 1 | NCT05304442 |
| Norelgestromin Patch | II | 1 | NCT07083635 |
Sorted by most advanced phase and number of active trials.
All 3 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Postpartum hemorrhage 4 drugs
- Menorrhagia 4 drugs
- Metrorrhagia 4 drugs
- Leiomyoma 9 drugs
- Venous thromboembolism 17 drugs
- Venous thrombosis 12 drugs
- Pulmonary embolism 11 drugs
- Thrombophilia 4 drugs
- Pre-eclampsia 23 drugs
- Agnosia 19 drugs
- Hemorrhage 25 drugs
- Von Willebrand's disease 8 drugs
Broader categories
- Female urogenital disease 11 drugs
- Female urogenital diseases and pregnancy complications 3 drugs
- Urogenital Diseases 16 drugs
- Genital Diseases, Female 6 drugs
- Genital Diseases 7 drugs
- Hemorrhage 25 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D014592 “Uterine Hemorrhage”.